George D. Demetri, MD

Videos

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses how sarcoma is leading the way in the breakdown of cancers into different types.

Breaking Down Sarcoma, Other Cancers Into Different Types

George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.

The Convergence of Targeted Therapies and Immuno-Oncology in Sarcoma

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.

In this preplanned analysis, researchers were trying to limit any excess heterogeneity in order to get a clear answer as to whether trabectedin is more active than dacarbazine. There is no question, Demetri says, that there was a progression-free survival (PFS) difference but no overall survival (OS) difference.

Demetri says the lack of OS difference was due to post-study therapies  virtually all patients went on to receive other agents after this protocol. It's worth noting, he says, that the trial was designed in 2010 and pazopanib (Votrient) was approved in 2012.

George D. Demetri, MD | Authors

Articles

Breaking Down Sarcoma, Other Cancers Into Different Types

The Convergence of Targeted Therapies and Immuno-Oncology in Sarcoma

Dr. George D. Demetri on Trabectedin or Dacarbazine Treatments for Patients With Advanced Leiomyosarcoma or Liposarcoma